Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus

This study aimed to evaluate ertugliflozin in patients with overweight and obesity with type 2 diabetes mellitus.

[1]  S. Terra,et al.  Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies , 2019, Diabetes & vascular disease research.

[2]  S. Engel,et al.  Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin , 2019, Current medical research and opinion.

[3]  B. Charbonnel,et al.  Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET trial , 2019, Diabetes, obesity & metabolism.

[4]  J. Eriksson,et al.  Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity , 2019, Drugs.

[5]  8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2019 , 2018, Diabetes Care.

[6]  Vertis-Cv Investigators.  Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV) , 2018 .

[7]  Geltrude Mingrone,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2018, Diabetes Care.

[8]  S. Goh,et al.  Weight loss associated with sodium‐glucose cotransporter‐2 inhibition: a review of evidence and underlying mechanisms , 2018, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[9]  C. Cannon,et al.  DESIGN AND BASELINE CHARACTERISTICS OF THE EVALUATION OF ERTUGLIFOZIN EFFICACY AND SAFETY CARDIOVASCULAR OUTCOMES TRIAL (VERTIS-CV) , 2018 .

[10]  J. Rosenstock,et al.  Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET) , 2018, Diabetes, obesity & metabolism.

[11]  K. Saunders,et al.  Pharmacotherapy for obesity in individuals with type 2 diabetes , 2018, Expert opinion on pharmacotherapy.

[12]  R. Pratley,et al.  Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial , 2018, Diabetes, obesity & metabolism.

[13]  S. Engel,et al.  Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study , 2018, Diabetes Therapy.

[14]  L. Ji,et al.  The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta‐Analysis , 2018, Obesity.

[15]  S. Engel,et al.  Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study , 2017, Diabetes, obesity & metabolism.

[16]  S. Engel,et al.  Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study , 2017, Diabetes Therapy.

[17]  G. Grunberger,et al.  Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study , 2017, Diabetes Therapy.

[18]  K. Gudzune,et al.  Treatment of Obesity in Patients With Diabetes , 2017, Diabetes Spectrum.

[19]  D. Hinnen.  Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes , 2017, Diabetes Spectrum.

[20]  M. Davies,et al.  Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone , 2017, Diabetes, obesity & metabolism.

[21]  J. Rosenstock,et al.  Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial , 2017, Diabetes Care.

[22]  J. Schoueri,et al.  Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus. , 2017, European review for medical and pharmacological sciences.

[23]  L. Ji,et al.  Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis , 2016, PloS one.

[24]  É. Hardy,et al.  Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. , 2016, The lancet. Diabetes & endocrinology.

[25]  D. Fitchett,et al.  Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.

[26]  K. Khunti,et al.  Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis , 2016, Diabetes, obesity & metabolism.

[27]  L. de las Fuentes,et al.  Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity. , 2016, Cell metabolism.

[28]  Fei Chang,et al.  Efficacy and safety of canagliflozin in patients with type 2 diabetes , 2016, Medicine.

[29]  R. Angermund,et al.  The Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2 Diabetes Mellitus (T2DM). , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[30]  Zhuang Miao,et al.  Pharmacokinetics, Metabolism, and Excretion of the Antidiabetic Agent Ertugliflozin (PF-04971729) in Healthy Male Subjects , 2013, Drug Metabolism and Disposition.

[31]  D. Matthews,et al.  Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.

[32]  Bo Feng,et al.  Preclinical Species and Human Disposition of PF-04971729, a Selective Inhibitor of the Sodium-Dependent Glucose Cotransporter 2 and Clinical Candidate for the Treatment of Type 2 Diabetes Mellitus , 2011, Drug Metabolism and Disposition.

[33]  S. Bangalore,et al.  Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials , 2011, Circulation.

[34]  N. Marchionni,et al.  Predictors of response to dipeptidyl peptidase‐4 inhibitors: evidence from randomized clinical trials , 2011, Diabetes/metabolism research and reviews.

[35]  A. Kengne,et al.  The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. , 2010, Diabetes research and clinical practice.

[36]  Craig I Coleman,et al.  Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. , 2010, JAMA.

[37]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[38]  B. Zinman,et al.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.

[39]  S. Saydah,et al.  Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. , 2004, JAMA.

[40]  D. Arnold,et al.  Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control. , 2000, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[41]  M Nurminen,et al.  Comparative analysis of two rates. , 1985, Statistics in medicine.